Myeloid Therapeutics Gets Fast Track Status for MT-101 Lymphoma Drug
Myeloid Therapeutics has received FDA’s Fast Track designation for its MT-101 candidate for refractory or relapsed CD5+ peripheral T cell lymphoma.
MT-101 is an immunotherapy drug that recognizes cancer cells, produces anti-tumor cytokines and ultimately kills the cancer.
The dose-escalation portion of the phase 1 study, with and without conditioning therapy, is now enrolling patients, the company said.
The FDA’s Fast Track designation is designed to facilitate development and expedite the review of therapies with the potential to treat serious or life-threatening conditions and fill an unmet medical need.